ASPIRE BIOPHARMA HOLDINGS, INC.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | 5,363.2% | 5,363.2% | -8.7% |
| FY2022 | -33.6% | -33.6% | 1.1% |
| FY2023 | -915.0% | -915.0% | 22.3% |
| FY2024 | 85.1% | 85.1% | -885.1% |
| FY2025 | 383.9% | 383.9% | -1,865.7% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | 5,363.2% | 5,363.2% | -8.7% |
| FY2022 | -33.6% | -33.6% | 1.1% |
| FY2023 | -915.0% | -915.0% | 22.3% |
| FY2024 | 85.1% | 85.1% | -885.1% |
| FY2025 | 383.9% | 383.9% | -1,865.7% |